Safety and tolerability of fentanyl sublingual spray during the titration phase of two phase 3 clinical trials: results from pooled data

被引：0
|
作者：
Rauck, R. [1 ]
Stearns, L. [1 ]
Forman, N. [1 ]
Parikh, N. [1 ]
Dillaha, L. [1 ]
机构：
[1] INSYS Therapeut, Chandler, AZ USA
来源：
JOURNAL OF PAIN | 2014年 / 15卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
365
引用
收藏
页码：S67 / S67
页数：1
相关论文
共 50 条
  • [1] SAFETY AND TOLERABILITY OF FENTANYL SUBLINGUAL SPRAY DURING THE TITRATION PHASE OF TWO PHASE 3 CLINICAL TRIALS: A POOLED ANALYSIS
    Rauck, Richard
    Stearns, Lisa
    Forman, Nicole
    Parikh, Neha
    ONCOLOGY NURSING FORUM, 2015, 42 (02) : E225 - E225
  • [2] Safety and tolerability of fentanyl sublingual spray during titration and maintenance therapy across a wide dose range in two phase 3 clinical trials
    Rauck, R.
    Stearns, L.
    Forman, N.
    Parikh, N.
    Dillaha, L.
    JOURNAL OF PAIN, 2014, 15 (04): : S67 - S67
  • [3] Safety and tolerability of apremilast up to 182 weeks: pooled analyses from Phase 3 clinical trials
    Papp, K.
    Sobell, J.
    Shah, K.
    Day, R.
    Chen, R.
    Paul, C.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2016, 30 : 67 - 68
  • [4] Safety and tolerability of apremilast up to 182 weeks: Pooled analyses from phase 3 clinical trials
    Papp, Kim
    Sobell, Jeffrey
    Shah, Kamal
    Day, Robert
    Chen, Rongdean
    Paul, Carle
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : AB269 - AB269
  • [5] Bempedoic acid safety analysis: Pooled data from four phase 3 clinical trials
    Bays, Harold E.
    Banach, Maciej
    Catapano, Alberico L.
    Duell, P. Barton
    Gotto, Antonio M., Jr.
    Laufs, Ulrich
    Leiter, Lawrence A.
    Mancini, G. B. John
    Ray, Kausik K.
    Bloedon, LeAnne T.
    Sasiela, William J.
    Ye, Zhan
    Ballantyne, Christie M.
    JOURNAL OF CLINICAL LIPIDOLOGY, 2020, 14 (05) : 649 - +
  • [6] POOLED SAFETY DATA FROM TWO PHASE 3 TRIALS OF A VAGINAL PH MODULATOR: RESULTS FROM AMPOWER AND AMP001
    Lee, T.
    Culwell, K.
    Dart, C.
    Howard, B.
    CONTRACEPTION, 2021, 104 (04) : 463 - 463
  • [7] SECUKINUMAB SAFETY AND TOLERABILITY IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND PSORIASIS: RESULTS FROM A POOLED SAFETY ANALYSIS OF SEVEN INTERNATIONAL PHASE 3 TRIALS
    Soriano, Enrique
    Gottlieb, Alice
    McInnes, Ian B.
    Mease, Philip
    Mpofu, Shephard
    Widmer, Albert
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2016, 22 (03) : 140 - 140
  • [8] Bimekizumab Safety in Patients With Moderate to Severe Plaque Psoriasis Pooled Results From Phase 2 and Phase 3 Randomized Clinical Trials
    Gordon, Kenneth B.
    Langley, Richard G.
    Warren, Richard B.
    Okubo, Yukari
    Gold, Linda Stein
    Merola, Joseph F.
    Peterson, Luke
    Wixted, Krista
    Cross, Nancy
    Deherder, Delphine
    Thaci, Diamant
    JAMA DERMATOLOGY, 2022, 158 (07) : 735 - 744
  • [9] Safety and Tolerability of Secukinumab in Patients With Active Ankylosing Spondylitis: Pooled Safety Analysis of Two Phase 3, Randomized, Controlled Trials
    Kyburz, D.
    Deodhar, A.
    Baeten, D.
    Sieper, J.
    Porter, B.
    Widmer, A.
    Richards, H.
    SWISS MEDICAL WEEKLY, 2016, 146 : 6S - 6S
  • [10] Safety and Tolerability of Secukinumab in Patients with Active Ankylosing Spondylitis: Pooled Safety Analysis of Two Phase 3, Randomized, Controlled Trials
    Deodhar, Atul A.
    Baeten, Dominique
    Sieper, Joachim
    Porter, Brian
    Widmer, Albert
    Richards, Hanno
    ARTHRITIS & RHEUMATOLOGY, 2015, 67
12345